🇺🇸 FDA
Patent

US 10478430

Compounds useful as inhibitors of ATR kinase and combination therapies thereof

granted A61KA61K31/496A61K31/4965

Quick answer

US patent 10478430 (Compounds useful as inhibitors of ATR kinase and combination therapies thereof) held by Vertex Pharmaceuticals Incorporated expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/496, A61K31/4965, A61K31/497, A61K31/55